452 related articles for article (PubMed ID: 10999739)
61. Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins.
Olsen RJ; Hinrichs SH
Oncogene; 2001 Mar; 20(14):1756-64. PubMed ID: 11313922
[TBL] [Abstract][Full Text] [Related]
62. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
[TBL] [Abstract][Full Text] [Related]
63. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
[TBL] [Abstract][Full Text] [Related]
64. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes.
Matsumoto Y; Tanaka K; Nakatani F; Matsunobu T; Matsuda S; Iwamoto Y
Br J Cancer; 2001 Mar; 84(6):768-75. PubMed ID: 11259090
[TBL] [Abstract][Full Text] [Related]
65. Novel replication inhibitory function of the developmental regulator/transcription repressor protein WT1 encoded by the Wilms' tumor gene.
Anant S; Axenovich SA; Madden SL; Rauscher FJ; Subramanian KN
Oncogene; 1994 Nov; 9(11):3113-26. PubMed ID: 7936634
[TBL] [Abstract][Full Text] [Related]
66. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
Zhang X; Xing G; Saunders GF
Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
[TBL] [Abstract][Full Text] [Related]
67. The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator.
Fujimura Y; Ohno T; Siddique H; Lee L; Rao VN; Reddy ES
Oncogene; 1996 Jan; 12(1):159-67. PubMed ID: 8552387
[TBL] [Abstract][Full Text] [Related]
68. Biology of EWS/ETS fusions in Ewing's family tumors.
Arvand A; Denny CT
Oncogene; 2001 Sep; 20(40):5747-54. PubMed ID: 11607824
[TBL] [Abstract][Full Text] [Related]
69. LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor.
Liu J; Nau MM; Zucman-Rossi J; Powell JI; Allegra CJ; Wright JJ
Genes Chromosomes Cancer; 1997 Mar; 18(3):232-9. PubMed ID: 9071577
[TBL] [Abstract][Full Text] [Related]
70. Lack of matrix metalloproteinase (MMP)-1 and -3 expression in Ewing sarcoma may be due to loss of accessibility of the MMP regulatory element to the specific fusion protein in vivo.
Yabe H; Fukuma M; Urano F; Yoshida K; Kato S; Toyama Y; Hata J; Umezawa A
Biochem Biophys Res Commun; 2002 Apr; 293(1):61-71. PubMed ID: 12054564
[TBL] [Abstract][Full Text] [Related]
71. Antisense transcripts and protein binding motifs within the Wilms tumour (WT1) locus.
Campbell CE; Huang A; Gurney AL; Kessler PM; Hewitt JA; Williams BR
Oncogene; 1994 Feb; 9(2):583-95. PubMed ID: 8290269
[TBL] [Abstract][Full Text] [Related]
72. Differential regulation of the Wilms' tumor gene, WT1, during differentiation of embryonal carcinoma and embryonic stem cells.
Scharnhorst V; Kranenburg O; van der Eb AJ; Jochemsen AG
Cell Growth Differ; 1997 Feb; 8(2):133-43. PubMed ID: 9040935
[TBL] [Abstract][Full Text] [Related]
73. The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein.
Karnieli E; Werner H; Rauscher FJ; Benjamin LE; LeRoith D
J Biol Chem; 1996 Aug; 271(32):19304-9. PubMed ID: 8702614
[TBL] [Abstract][Full Text] [Related]
74. Donor splice-site mutations in WT1 are responsible for Frasier syndrome.
Barbaux S; Niaudet P; Gubler MC; Grünfeld JP; Jaubert F; Kuttenn F; Fékété CN; Souleyreau-Therville N; Thibaud E; Fellous M; McElreavey K
Nat Genet; 1997 Dec; 17(4):467-70. PubMed ID: 9398852
[TBL] [Abstract][Full Text] [Related]
75. The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator.
Labelle Y; Bussières J; Courjal F; Goldring MB
Oncogene; 1999 May; 18(21):3303-8. PubMed ID: 10359536
[TBL] [Abstract][Full Text] [Related]
76. Cryptic exons as a source of increased diversity of Ewing tumor-associated EWS-FLI1 chimeric products.
Kovar H; Jugovic D; Melot T; Zoubek A; Lenoir G; Fink FM; Philip I; Turc-Carel C; Thomas G; Zucman-Rossi J
Genomics; 1999 Sep; 60(3):371-4. PubMed ID: 10493837
[TBL] [Abstract][Full Text] [Related]
77. Characterization of the malignant melanoma of soft-parts cell line GG-62 by expression analysis using DNA microarrays.
Schaefer KL; Wai DH; Poremba C; Korsching E; van Valen F; Ozaki T; Boecker W; Dockhorn-Dworniczak B
Virchows Arch; 2002 May; 440(5):476-84. PubMed ID: 12021921
[TBL] [Abstract][Full Text] [Related]
78. Analysis of possible WT1 RNA processing in primary Wilms tumors.
Gunning KB; Cohn SL; Tomlinson GE; Strong LC; Huff V
Oncogene; 1996 Sep; 13(6):1179-85. PubMed ID: 8808692
[TBL] [Abstract][Full Text] [Related]
79. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses.
Panagopoulos I; Mertens F; Dêbiec-Rychter M; Isaksson M; Limon J; Kardas I; Domanski HA; Sciot R; Perek D; Crnalic S; Larsson O; Mandahl N
Int J Cancer; 2002 Jun; 99(4):560-7. PubMed ID: 11992546
[TBL] [Abstract][Full Text] [Related]
80. EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity.
Liu C; Calogero A; Ragona G; Adamson E; Mercola D
Crit Rev Oncog; 1996; 7(1-2):101-25. PubMed ID: 9109500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
